- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05532566
Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
Quercus Ilex and Quercus Robur Allergen Extracts. Determination of the in Vivo Allergenic Potency in Histamine Equivalent Units (HEP).
Study Overview
Status
Intervention / Treatment
Detailed Description
The trial will consist of a single visit, in which the following procedures will be carried out:
- Demographic data.
- Clinical history.
- Inclusion/exclusion criteria.
- General examination.
- Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control).
- Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed.
- Evaluation of adverse events.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Raquel Caballero
- Phone Number: 34 607600638
- Email: rcaballero@inmunotek.com
Study Contact Backup
- Name: Miguel Casanovas
- Phone Number: 34 912908942
- Email: mcasanovas@inmunotek.com
Study Locations
-
-
-
Madrid, Spain
- Clínica Subiza, centro de asma y alergia
-
Principal Investigator:
- Javier Subiza, DM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must live in a geographical area where allergic problems caused by Quercus ilex and Quercus robur are relevant.
- Positive clinical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to asthma) to Quercus ilex and Quercus robur.
- A positive prick-test (mean papule diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against that allergen.
- The mean papule area obtained with Histamine dichlorhydrate at 10 mg/mL should be ≥ 7 mm2.
- Age: Between 18 and 64 years old.
- Subjects must be able to give informed consent.
Exclusion Criteria:
- Subjects should not be excluded in terms of low or high sensitivity to Quercus ilex and Quercus robur.
- Subjects outside the age range.
- Subjects who have previously received immunotherapy in the last 5 years for the treatment of asthma or rhinoconjunctivitis for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Quercus ilex and Quercus robur extracts.
- Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated.
- Subjects who have previously presented a severe secondary reaction during the performance of diagnostic skin tests by prick test.
- Subjects under treatment with ß-blockers.
- Subjects clinically unstable (acute asthma, febrile, etc.).
- Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives).
- Subjects with active viral infection by herpes simplex or herpes varicella zoster in the area where the prick test is performed.
- Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HTA, cardiopathy, etc.).
- States of the subject in which he/she cannot offer cooperation and severe psychiatric disorders.
- Pregnant women or women at risk of pregnancy and lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Extract Q. ilex + extract Q. robur + positive control + negative control
There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10mg/mL) and the negative control, with prick test. Quercus ilex: 2,500, 500 and 100 μg/mL Quercus robur: 2,500, 500 and 100 μg/mL |
In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control.
The application will be made in duplicate on the anterior face of the subject's arm.
The distance between each application should be approximately 4 cm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Size of the induced papule on the skin
Time Frame: 15 minutes
|
Size of the induced papule on the skin when applying each of the concentrations of the allergenic extracts and the positive (histamine) and negative controls, using the prick test.
|
15 minutes
|
Adverse reactions
Time Frame: 30 minutes
|
Mild secondary reactions such as pruritus, erythema, local edema, etc.
There is a risk, infrequent and exceptional, of systemic reactions, sometimes severe (urticaria, asthma, anaphylactic shock, etc.).
|
30 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Javier Subiza, DM, Clínica Subiza, centro de asma y alergia
Publications and helpful links
General Publications
- Sjoholm I. Standardisation of allergens in Europe. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1997;(91):107-10.
- Larsen JN, Dreborg S. Standardization of Allergen Extracts. Methods Mol Biol. 2019;2020:63-76. doi: 10.1007/978-1-4939-9591-2_5.
- Arntzen FC. Progress in common Nordic Guidelines for the Registration of Allergen Preparations. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M. 1983;(78):25-8. No abstract available.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T525-STD-043
- 2020-005388-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Reaction
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAllergic Reactions
-
PharmAthene, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedAllergic ReactionsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAllergic Reactions
-
Michel BouvierClinique Charcot; Polyclinique du BeaujolaisCompletedOral Allergic Syndrome | Allergic Reaction Caused by Food (Disorder)
-
St. Louis UniversityCompletedAdverse Reaction to Drug | Allergic Reaction to Contrast MediaUnited States
-
Groupe Hospitalier Paris Saint JosephActive, not recruitingAllergic Reaction | Beta Lactam Adverse ReactionFrance
-
Northern Orthopaedic Division, DenmarkAalborg UniversityNot yet recruitingAllergic Reaction
-
University Hospital, Strasbourg, FranceCompletedAllergic ReactionFrance
-
University of SaskatchewanCompleted
Clinical Trials on Allergenic extract
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Perennial Allergic RhinitisUnited States
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Inner-City Asthma ConsortiumCompleted
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | AllergyUnited States
-
Antigen Laboratories, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompleted
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Perennial Allergic RhinitisUnited States
-
Inmunotek S.L.Not yet recruitingAllergic Reaction | Allergic Skin Reaction | Allergy PollenSpain
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Rhinitis, Allergic, PerennialUnited States
-
Greer LaboratoriesCompletedAllergic RhinitisUnited States
-
Leti Pharma GmbHPierrel Research Europe GmbH; Laboratorios LETI SL (Study Medication); Labor...CompletedAllergic Rhinitis and/or Rhinoconjunctivitis +- Asthma | Immunotherapy, AllergenGermany, Lithuania, Poland